ClinVar Miner

Submissions for variant NM_007327.4(GRIN1):c.1858G>C (p.Gly620Arg)

dbSNP: rs797045047
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Baylor Genetics RCV000191091 SCV000245488 likely pathogenic Intellectual disability, autosomal dominant 8 2014-10-21 criteria provided, single submitter clinical testing Likely pathogenicity based on finding it twice in our laboratory de novo: in a 24-year-old female with absent speech, autism, intellectual disability, mild unilateral conductive hearing loss, spasticity, joint laxity, failure to thrive, gastroesophageal disorder, strabismus, myopia, mild mitral valve prolapse, intermittent episodes of syncope, and scoliosis; in a 7-year-old male with absent speech, regression, intellectual disability, congenital hypotonia, movement disorder, short stature
GeneDx RCV000479068 SCV000569832 pathogenic not provided 2023-01-21 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect: loss of NMDA receptor function (Lemke et al., 2016; Chen et al., 2017); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27164704, 26633545, 28228639, 31487502, 31429998)
Ambry Genetics RCV000622498 SCV000742522 likely pathogenic Inborn genetic diseases 2018-12-24 criteria provided, single submitter clinical testing The p.G620R variant (also known as c.1858G>C), located in coding exon 13 of the GRIN1 gene, results from a G to C substitution at nucleotide position 1858. The glycine at codon 620 is replaced by arginine, an amino acid with dissimilar properties. This alteration has been reported in individuals with intellectual disability and has been shown to have an impact on protein function (Lemke JR et al. Neurology, 2016 06;86:2171-8; Chen W et al. J. Hum. Genet., 2017 Jun;62:589-597). In addition, this variant has been determined to be the result of a de novo mutation or germline mosaicism in one individual with global developmental delay and hypotonia (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne RCV001526577 SCV001737004 pathogenic Seizure criteria provided, single submitter research
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center RCV000479068 SCV002051694 pathogenic not provided 2021-01-19 criteria provided, single submitter clinical testing PS3, PP2, PP3, PM1, PM2, PS4_Moderate
Invitae RCV000191091 SCV002240115 pathogenic Intellectual disability, autosomal dominant 8 2023-11-27 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 620 of the GRIN1 protein (p.Gly620Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of autosomal dominant GRIN1-related conditions (PMID: 28228639, 34884460). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 209159). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GRIN1 protein function. Experimental studies have shown that this missense change affects GRIN1 function (PMID: 28228639, 31429998). For these reasons, this variant has been classified as Pathogenic.
CeGaT Center for Human Genetics Tuebingen RCV000479068 SCV002498081 pathogenic not provided 2022-03-01 criteria provided, single submitter clinical testing GRIN1: PS2, PM1, PM2, PP2, PP3, PS3:Supporting
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000191091 SCV002511789 pathogenic Intellectual disability, autosomal dominant 8 2022-04-16 criteria provided, single submitter clinical testing Variant summary: GRIN1 c.1858G>C (p.Gly620Arg) results in a non-conservative amino acid change located in the Ionotropic glutamate receptor domain (IPR001320) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 244402 control chromosomes. c.1858G>C has been reported in the literature as a de-novo variant in multiple individuals affected with features of Autosomal Dominant Neurodevelopmental Disorder With Or Without Hyperkinetic Movements And Seizures (example, Chen_2017, Lemke_2016, Costain_2019, Li_2019, Santos-Gomez_2021). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function reporting a reduction in N-methyl-D-aspartate (NMDAR) receptor trafficking, expression and function (example, Chen_2017). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
OMIM RCV000191091 SCV000678284 pathogenic Intellectual disability, autosomal dominant 8 2022-03-28 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.